Portal de Periódicos da CAPES

Response of the nonaliergic rhinitis with eosinophilia (HARES) syndrome to 4% cromolyn sodium nasal solution

1982; Elsevier BV; Volume: 70; Issue: 2 Linguagem: Inglês

10.1016/0091-6749(82)90240-8

1097-6825

Bruce L. Nelson, Robert L. Jacobs,

Contact Dermatitis and Allergies

Abstract A double-blind, parallel, multiple-dose drug trial was perforated on 23 adult patients with nonallergic rhinitis with eosinophilia (HARES) syndrome. All patients were characterized clinically as having perennial nasal symptoms of sneezing paroxysms, profuse watery rhinorrhea, and pruritus of the nasopharyngeal and conjunctiva( mucosa, with minimal nasal obstruction to airflow. They had nasal secretion eosinophilia, negative prick or intradermal immediate skin tests, negative serum RAST results to common inhalant allergens, negative methacholine bronchoprovocation challenges, and normal total eosinophil counts and total serum IgE levels. Twelve patients received a 4% cromolyn sodium nasal solution and/I patients received a matching placebo administered six times daily. for 8 wk. Daily symptom scores for itchy nose, runny nose, 'stuffy nose, itchy eyes, itchy throat, mouth breathing, postnasal drainage, sneezing, and nose blowing were recorded by the patients. Eye, ear, nose, and throat (SENT) examinations were performed weekly by one of the investigators, and blood samples for CBC and chemistries were obtained at the start and termination of the study. Chemistries and blood counts showed no adverse effects of the drug. No important differences between the drug and placebo groups were noted in either the .symptom scores or SENT examinations of the two groups. We conclude that 4% cromolyn sodium nasal solution is of no benefit in the treatment of patients with the HARES syndrome.